Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.

American journal of epidemiology - 15 Dec 2007

Rebbeck T R, Troxel A B, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin J A, Strom B L

Abstract excerpt

Combined hormone replacement therapy (CHRT) containing estrogens and progestins is associated with breast cancer risk. The authors evaluated interactions between CHRT use and progestin metabolism genotypes at CYP3A4 and the progesterone receptor (PGR) and their effects on breast cancer risk using the population-based Women's Insights and Shared Experiences (WISE) Study (1999-2002) of postmenopausal Caucasian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen Replacement Therapy
Share to Estrogens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pennsylvania

Share to Population Surveillance

Share to Postmenopause

Share to Progesterone

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Identifiers

PMID: 17827444
DOI: 10.1093/aje/kwm239

Genes

PGR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.PMID 17827444Read ↗

Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.Semantic proximity Read ↗

Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.Semantic proximity Read ↗

Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.Semantic proximity Read ↗

Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype.Semantic proximity Read ↗

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.Semantic proximity Read ↗

Progesterone Receptor Gene Polymorphisms and Breast Cancer Risk.Semantic proximity Read ↗

Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women.Semantic proximity Read ↗

Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism.Semantic proximity Read ↗

Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Estrogen-related genes and their contribution to racial differences in breast cancer risk.Semantic proximity Read ↗

Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.